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Phytoestrogens on coagulation and microparticles 711postmenopausal
womenMethods: The original study is a 2-year prospective, double-blind, placebo-controlled study. In
total, 431 postmenopausal women (from 3 medical centers) were randomly assigned to receive
either high-dose isoflavone or placebo for 2 years. At baseline, 6 months, 1 year, and 2 years
after treatment, blood pressure, body weight, liver function tests, hematological parameters,
and lipid profiles were measured. The 1st year blood specimens of 85 cases of 144 eligible par-
ticipants (from one of the three centers) were analyzed as D-dimer, von Willebrand factor an-
tigen, factor VII, plasminogen activator inhibitor type 1, and circulating cellular
microparticles, including the measurement of monocyte, platelet, and endothelial micropar-
ticles.
Results: In the isoflavone group, after 1 year, the changes in liver function tests, hematological
parameters, and coagulation tests were not different from those of the control. Triglyceride
levels were significantly lower after 6 months of isoflavone treatment than the placebo group,
but the difference did not persist after 1 year. Endothelial microparticles increased steadily in
both groups during the 1-year period but the trend was not affected by treatment.
Conclusion: The results of the present study indicate that high-dose isoflavone treatment
(300 mg/day) does not cause hematological abnormalities or activate coagulation factors.
Copyright ª 2013, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.Introduction
Ever since hormone replacement therapy was reported to
cause early adverse effects on cardiovascular risk,1,2 much
research has been directed towards developing new treat-
ments that show cardiovascular safety in postmenopausal
women.
Phytoestrogens are a diverse group of non-steroidal
plant-derived compounds that are structurally similar to
estradiol and have a weak affinity on estrogen receptors.3
Many kinds of food contain phytoestrogens. Soybeans, one
of the most common sources of plant estrogens, are
particularly rich in isoflavones (the main effective com-
pounds of phytoestrogens). Soy proteins have been re-
ported to have beneficial effects on cardiovascular and
skeletal health in postmenopausal women.3
Despite the reported benefits of phytoestrogens, there
are still safety concerns about their long-term usage.4,5 One
of the concerns is subclinical lymphocytopenia. A multi-
center study showed that around 13% of postmenopausal
women who daily received 600 mg ipriflavone, a synthetic
isoflavone, for 3 years developed lymphocytopenia
(lymphocyte counts < 500  106/L).6 A similar observation
was reported by Agnusdei and Bufalino7 that 2 years of
ipriflavone supplementation caused approximately 3% of
participants to have subclinical low lymphocyte counts.
Although a subsequent study showed that soy protein sup-
plementation, unlike synthetic isoflavone, did not cause
lymphocytopenia in postmenopausal women, the dose used
in that study was about 10% of the former two.8
Another concern is about the estrogenic effect of phyto-
estrogen. Estrogen therapyhas been found to cause increased
early risk of coronary heart disease, as well as an increased
risk of stroke and venous thromboembolism.1,2,9 Given the
structural similarity of isoflavones to estrogen and the po-
tential importance of the prothrombotic effects of estrogen,
the effect of isoflavones on hemostasis is also of interest.
The traditional dosage for isoflavone intervention ranges
from 20 mg to 90 mg, that is, <100 mg.10e12 However, ac-
cording to the comparison that estrogenic activity of 200 mg
isoflavone is approximately equivalent to 0.4e2.0 mg ofestradiol,13,14 so the phytoestrogen dosage used in the pre-
vious studies on protective effect of bone may be subopti-
mal. Besides, the optimal dose of isoflavone as hormone
replacement therapy in postmenopausal women is still un-
certain, and the safety of high-dose (250e300 mg/day) iso-
flavone has not adequately addressed previously.
Circulating cellular microparticles are intact vesicles
shed from cell membranes, ranging in size from 0.2 mm to
2.0 mm in diameter.15e17 They arise mainly through cell
membrane activation processes, and through apoptosis.
Microparticles originating from platelets, endothelial cells,
and monocytes have been most extensively studied in
various clinical settings, such as cardiovascular disease,
inflammation, and metabolic syndromes.16,18 Only recently
have they been proposed in postmenopausal women as a
predictive factor for premature coronary calcification.19
In this study, we investigated the effects of phytoes-
trogen on coagulation function, by giving the participants, a
12-month treatment of isoflavone and determining the ef-
fects on homeostatic factors, hematological parameters
and cellular microparticles. The pharmacological dose of
isoflavone (300 mg/day) used in this study was higher than
previous studies,10e12 and would provide more informative
data about its safety profile in clinical practice. Partici-
pants in this study were originally enrolled in the Taiwan
Isoflavones Multicenter Study (TIMS).20
Materials and methods
The TIMS was a 2-year prospective, double-blinded clinical
trial conducted at three medical centers in Taiwan: the
National Taiwan University Hospital, Changhua Christian
Hospital, and National Cheng Kung University Hospital, from
which 144, 142, and 145 (total, 431) participants were
recruited, respectively.
Participants were aged 45e65 years (mean  standard
deviation 57.6  3.0 years). All participants’ final menstru-
ationwas between 12months and 10 years prior to the study.
Their baseline follicle stimulating hormone levels were
40 mIU/mL. The bone mineral density of the second to
fourth lumbar vertebrae was 1 standard deviation below the
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The participants were randomly assigned to receive 1 year of
oral isoflavone (isoflavone aglycone 300 mg/day; Taiwan
Biotech Co. Ltd., Taoyuan, Taiwan; nZ 41) or placebo tab-
lets (nZ 41). All participants received calcium, 500mg/day,
and vitamin D, 62.5 IU/day, orally. The researchers and
participants were blind to the assignment. Informed consent
was obtained from all participants. The study protocol was
approved by the Ethic Committee of the National Taiwan
University Hospital, and Human Ethics Committee of the
National Health Research Institutes, Taiwan.
In this study, the participants included are a subset of
those enrolled in TIMS.20 Of the 144 eligible participants
enrolled at the National Taiwan University Hospital, 85 (59%)
were enrolled in this study, the 1st year blood specimens of 85
cases (59%) were used and analyzed in this study.
Blood specimen collection
We made use of the residual specimens of TIMS20; briefly:
fasting morning blood samples were collected at baseline, 6
months, and 12 months. Venous blood was obtained and
placed into plain tubes for lipid and biochemistry study, and
into 3.8% citrate tubes (9:1 ratio) for coagulation and
cellular microparticle studies. These samples were imme-
diately centrifuged and sera or plasma were immediately
stored at 80 C prior to analysis.
Laboratory analyses
Blood biochemistry and coagulation assays were performed
in the same manner as routine examinations in the labo-
ratory in the National Taiwan University Hospital. All sam-
ples from each participant were assayed in the same batch.
For blood chemistry studies, serum levels of aspartate
aminotransferase, alanine aminotransferase, total choles-
terol, and triglycerides were measured in the original study
based on enzymatic methods by TBA 200FR instruments
(Toshiba, Tokyo, Japan).20 Hematological parameters were
also previously analyzed with a routine blood counter
(XE2100; Sysmex Corp. Kobe, Hyogo, Japan). Factor VII level
was measured in a one-stage assay based on prothrombin
time using factor VII deficient plasma (Dade Behring, Mar-
burg, Germany) and a CA-1500 instrument (Sysmex). Total
protein S was measured based on inhibiting the clotting ac-
tivity of activated factor X and V by combination of activated
protein C and protein S using protein S and C4b binding pro-
tein deficient plasma (Sysmex). VWF-Ag was measured by a
latex agglutinin turbidity assay (Sysmex). Plasminogen acti-
vator inhibitor type 1 level was measured by a chromogenic
substrate assay (Sysmex). D-dimer level was measured by an
immunoturbidimetric assay (Sysmex).
Measurement of circulating cellular microparticles
Circulating cellular microparticles were measured by a flow
cytometer (FASCalibur; BD Bioscience, Franklin Lakes, NJ,
USA) using a method based on Chirinos et al.21 In brief,
platelet and endothelial microparticles were measured
simultaneously in citrated plasma by a pair of fluorescent
monoclonal antibodies: phycoerythrin-labeled anti-CD31 (BDBioscience) and fluorescein isothiocyanate-labeled anti
CD42b (BD Bioscience). Because CD31 was expressed on
platelet and endothelial microparticles, and CD42b was
expressed only on platelet microparticles, platelet micro-
particles were defined as events CD31þ/CD42bþ and endo-
thelialmicroparticles aseventsCD31þ/CD42be.Wealsoused
fluorescein isothiocyanate-labeled CD51/61 (BD Bioscience)
to mark a different phenotypic species of endothelial micro-
particles. Monocytic microparticles were measured with
fluorescein isothiocyanate-labeled anti-CD14 (BD Biosci-
ence). Values of microparticles are reported as counts/mL.
Statistical analysis
We performed repeated measurement of two-way analysis
of variance to compare differences of the mean body
weight, body height, body mass index, and biochemical and
homeostatic factors among baseline, 6 month, and 12 month
periods (within-subject effect) between the isoflavone and
placebo groups (between-subject effect). We also per-
formed the pairwise test in within-subject effect. The mean
ages of the isoflavone and placebo groups were compared
with Student t test. The above calculations were performed
using SPSS software version 16 (SPSS Inc., Chicago, IL, USA).
Results
Demographic characteristics
Eighty-two women completed the 1-year follow-up, one and
two participants in the isoflavone and placebo groups,
respectively, were lost to follow-up. Baseline characteristics
of the study population are shown in Table 1. The two groups
showed no significant differences in age, body weight, body
height, body mass index, systolic, and diastolic blood pres-
sure at baseline. Body weight and height remained un-
changed during the 1-year treatment period in both groups.
Slight decreases in systolic and diastolic blood pressures
within both groups were noted during the 12 months, but
with no significant differences between treatment groups.
Biochemical and hematological parameters
Table 2 shows the biochemical markers including liver
function tests and lipid profiles at baseline, 6 months, and
12 months. At 6 months after initiation, we observed a
statistically significant difference in triglyceride levels be-
tween the isoflavone and placebo groups, but the differ-
ence between the two groups disappeared at the 12-month
time point, indicating a transient effect. There were no
significant differences between the isoflavone and placebo
groups in levels of cholesterol, aspartate aminotransferase,
alanine aminotransferase, or any of the hematological pa-
rameters, such as hemoglobin, total white cell counts, and
lymphocyte counts, during the entire study period (Table 3).
Markers of coagulation and fibrinolysis
No significant differences were observed between the pla-
cebo and isoflavone groups for von Willebrand factor
Table 1 Clinical characteristics of patients in the isoflavone and placebo group at baseline and during follow-up.
Groups Baseline 6 months 12 months p**
Age (y) Isoflavone 56.1 (3.1) 0.13
Placebo 57.0 (2.9)
Weight (kg) Isoflavone 55.1 (6.3) 55.1 (6.0) 55.4 (6.3) 0.99
Placebo 55.1 (6.6) 55.1 (6.9) 55.2 (6.2)
Height (cm) Isoflavone 155.1 (4.2) 155.1 (4.2) 155.1 (4.2) 0.90
Placebo 154.8 (5.0) 154.8 (5.0) 154.1 (5.0)
BMI (kg/m2) Isoflavone 22.9 (2.6) 22.9 (2.4) 22.9 (2.4) 0.82
Placebo 23.1 (2.9) 23.0 (3.0) 23.0 (3.0)
SBP (mmHg) Isoflavone 119.0 (13.8) 115.0 (12.3)* 117.1 (11.1) 0.83
Placebo 117.5 (16.6) 114.2 (16.8)* 114.2 (15.4)
DBP (mmHg) Isoflavone 77.3 (9.3) 72.1 (9.1)* 73.3 (7.1)* 0.67
Placebo 74.6 (11.4) 72.7 (11.9)* 72.2 (10.5)*
Data are presented as mean ( standard deviation).
* p < 0.05 vs. baseline.
** p-value between 2 groups.
BMI Z body mass index; DBP Z diastolic blood pressure; SBP Z systolic blood pressure.
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Regarding to the fibrinolytic activities, plasminogen acti-
vator inhibitor type-1 levels increased slightly and signifi-
cantly at 6 months in both groups, but returned to baseline
at 12 months. There was no significant difference in D-
dimer levels between the placebo and isoflavone groups.
Plasma cellular microparticles levels
Plasma CD31þ42be endothelial microparticles increased at
12 months in both groups (Table 5), but CD31þ42bþ
platelet microparticles, CD51/61þ endothelial microparti-
cles and CD14þ monocyte microparticles remained un-
changed during the study period. No significant differences
were noted between the two groups for the above cellular
microparticle levels.
Discussion
Oral estrogen therapy has been associated with a decrease
in coagulation inhibitors, and increases in both thrombin
and plasmin production, and in fibrin degradation.22,23Table 2 Results of biochemical tests.
Groups Baseline
AST (U/L) Isoflavone 21.3 (4.0)
Placebo 24.2 (8.5)
ALT (U/L) Isoflavone 17.0 (5.5)
Placebo 21.6 (13.1)
TC (mg/dL) Isoflavone 208.8 (42.5)
Placebo 216.5 (34.7)
TG (mg/dL) Isoflavone 89.4 (46.4)
Placebo 105.5 (46.0)
Data are presented as mean ( standard deviation).
* p < 0.05 between 2 groups.
ALT Z alanine aminotransferase; AST Z aspartate aminotransferase;These changes occur 1 month after starting estrogen ther-
apy and could revert to baseline when treatment was
stopped. Oral estradiol also increased the plasma concen-
trations of Factor VII and Factor VIIa.9 Factor VII is impor-
tant for tissue factor-mediated coagulation. Our study
demonstrates that, unlike oral estrogen, isoflavone does
not cause a significant change in coagulation and fibrino-
lytic activity even at a dose of 300 mg/day. These results do
not support biologically significant estrogenic effects of
isoflavone on coagulation or fibrinolytic potential. We also
found that isoflavone did not cause hematological changes
in patients treated with 300 mg/day isoflavone for 1 year.
This finding is in accordance with data by Soung et al,8 who
showed that daily supplementation of 25 g soy protein
containing 60 mg isoflavones for 12 months did not alter
lymphocyte count in postmenopausal women.
Circulating cellular microparticles have been proposed
as an important marker for vascular and hemostatic dis-
eases.16,24 Most of the previous studies were focused on
patients with known risks, only recently have the studies of
cellular microparticles extended to asymptomatic pa-
tients.19,25 One of the studies found that elevated levels of
endothelial microparticles could define a group of newly6 months 12 months p
22.1 (5.7) 22.0 (4.1) 0.32
23.8 (9.4) 22.7 (7.6)
19.0 (7.8) 19.0 (6.1) 0.37
22.7 (13.5) 20.0 (9.4)
217.8 (32.6) 210.8 (29.2) 0.64
223.0 (37.9) 215.8 (39.6)
83.8 (30.1) 93.4 (39.8) 0.04*
101.3 (54.0) 114.2 (55.4)
TC Z total cholesterol; TG Z triglyceride.
Table 3 Hematological parameters.
Groups Baseline 6 months 12 months p*
Hemoglobin (g/dL) Isoflavone 13.18 (0.14) 13.33 (1.13) 13.32 (1.10) 0.12
Placebo 13.64 (0.84) 13.51 (0.79) 13.62 (0.90)
WBC ( 109/L) Isoflavone 4.90 (1.08) 4.84 (1.00) 5.13 (0.95) 0.30
Placebo 5.00 (1.10) 4.94 (1.12) 5.64 (1.76)
Lymphocytes ( 109/L) Isoflavone 1.73 (0.50) 1.70 (0.34) 1.70 (0.34) 0.83
Placebo 1.80 (0.49) 1.58 (0.44) 1.85 (0.57)
Monocytes ( 109/L) Isoflavone 0.23 (0.66) 0.20 (0.55) 0.22 (0.51) 0.38
Placebo 0.24 (0.08) 0.20 (0.61) 0.25 (0.94)
Platelets ( 109/L) Isoflavone 244.3 (49.3) 237.3 (46.9) 244.4 (47.7) 0.28
Placebo 229.3 (56.1) 229.9 (59.6) 230.5 (53.8)
Data are expressed as mean ( standard deviation).
* p-value between 2 groups.
WBC Z white blood cells.
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who otherwise were asymptomatic and had no other known
cardiovascular risk factors.19 Our studies further showed
that, in a comparable group of asymptomatic menopausal
women, the endothelial microparticles increased over the
12-month study period, and this trend could not be altered
by 300 mg isoflavone treatment. Given the observation that
endothelial microparticles are potentially an early marker
for cardiovascular disease in asymptomatic menopausal
women, our results warrant further larger scale studies.
Regarding the effects of isoflavone on lipid profiles,
previous studies of 10e90 mg daily short-term (1e6 months)
treatment showed beneficial effects with increasing high-
density lipoprotein cholesterol (HDL-C) and decreasing
total cholesterol/HDL-C ratio in hyperlipidemic patients,
but only increasing HDL-C levels in normolipidemic persons
under 34e56 mg daily isoflavone short-term (17 dayse6
weeks) intervention.26e29 In diabetic patients, 120e165 mg
daily isoflavone short-term (6e12 weeks) administration
decreased cardiovascular risk factors, such as a reduction
of low-density lipoprotein cholesterol and/or total choles-
terol.30 However, the sample sizes of these studies are all
small. The present study demonstrated a weak statistically
significance for lowering triglyceride level after 6 months ofTable 4 Coagulation and fibrinolytic activity data.
Groups Baseline
vWF-Ag Isoflavone 109.1 (29.3)
Placebo 114.3 (31.0)
Factor VII activity Isoflavone 119.5 (12.5)
Placebo 114.5 (17.1)
Protein S Isoflavone 88.3 (14.8)
Placebo 87.4 (12.7)
PAI-1 (U/mL) Isoflavone 3.89 (0.90)
Placebo 3.94 (0.85)
D-dimer (mg/mL) Isoflavone 1.33 (0.74)
Placebo 1.57 (1.67)
Data are expressed as mean ( standard deviation).
* Significantly different from those of baseline p < 0.05.
** p-value between 2 groups.
PAI-1 Z plasminogen activator inhibitor type-1; vWF-Ag Z von Willebhigh dose isoflavone treatment (p Z 0.034), but triglycer-
ide level returned to baseline at 12 months. These findings
demonstrate that the lipid-lowering effect of isoflavone,
even at 300 mg, is weak and temporal. The total cholesterol
level remained unchanged during the study period in both
groups.
Patients in both groups demonstrated decreases in the
systolic and diastolic blood pressure after 6 months. The
effect of reduction in diastolic blood pressure persisted
during the entire study period (Table 1). There was no
significant difference between control and isoflavone
groups during the overall study period. Several previous
studies have reported on the effect of a whole soy food on
blood pressure in hypertensive individuals. In men and
postmenopausal women, 34e118 mg isoflavone treatment
resulted in lowering of systolic and diastolic pressure.3 A
daily serving of 1000 g soy milk for 3 months can decrease
systolic and diastolic pressure in mild to moderated hy-
pertensive patients.31 In adults with borderline high blood
pressure, however, a daily dose of 55 mg isoflavones for 8
weeks failed to demonstrate the beneficial effect.32 In a
recent randomized controlled crossover study, soy nut
supplement, containing 25 g of soy protein and 101 mg of
aglycone isoflavone, lowered systolic and diastolic blood6 months 12 months p**
109.9 (30.4) 109.4 (34.4) 0.45
113.0 (29.7) 115.4 (33.2)
123.1 (14.0) 120.3 (15.8) 0.15
118.7 (15.5) 118.6 (13.9)
89.0 (10.6) 89.9 (14.5) 0.90
90.6 (16.7) 87.6 (15.7)
4.05 (1.02)* 3.77 (0.76) 0.63
4.14 (0.89)* 3.83 (0.75)
1.31 (0.77) 1.11 (0.70) 0.40
1.53 (1.62) 2.10 (3.58)
rand factor antigen.
Table 5 Cellular microparticle data.
Groups Baseline 6 months 12 months p**
CD14þ Monocyte Isoflavone 270.0 (342.3) 346.6 (430.0) 402.8 (678.3) 0.47
Placebo 534.6 (1135.0) 345.9 (467.3) 348.8 (490.8)
CD51/61þ Endothelial MP Isoflavone 38.0 (90.3) 46.0 (148.6) 90.6 (281.5) 0.36
Placebo 45.5 (60.6) 25.5 (16.5) 35.5 (86.8)
CD31þ/42bþ Platelet MP Isoflavone 439.9 (836.4) 356.8 (271.0) 390.4 (317.2) 0.38
Placebo 334.3 (736.4) 266.7 (392.5) 681.8 (1263.3)
CD31þ/CD42be Endothelial MP Isoflavone 28.8 (18.0) 28.7 (15.2) 36.3 (27.1)* 0.65
Placebo 24.1 (17.8) 29.0 (27.2) 35.5 (30.7)*
Data are expressed as mean ( standard deviation); all parameter units are particles/mL.
MP Z microparticles.
* Significantly different from those of baseline p < 0.05.
** p-value between groups.
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postmenopausal women. It seems that the blood pressure-
lowering effects were less consistent in normotensive
patients.33 In the present study, participants in both arms
demonstrated a similar level of reductions in systolic and
diastolic blood pressure during the study period, without a
significant difference between the two groups. However,
the reliability and reproducibility of blood pressure mea-
surement are not consistent due to numerous confounding
factors. In addition, we did not find blood pressure-
lowering effects by high-dose isoflavone in our study
cohort; the reduction of blood pressure in both groups may
be due to self-awareness about health after participation.
In summary, our findings suggest that high-dose isofla-
vone (up to 300 mg/day) for 1 year does not significantly
alter coagulation and hematological parameters in post-
menopausal women. The safety profile of high-dose isofla-
vone treatment may pave the way to investigate whether
high dose phytoestrogens can provide benefits for post-
menopausal women. We also observed that plasma levels of
cellular microparticles increased in postmenopausal women
whether they received isoflavone or placebo, suggesting
that further studies are needed to clarify if circulating
microparticles contribute to cardiovascular risk in post-
menopausal women.
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